Effective January 1, 2023, David Liu, Protagonist Therapeutics, Inc.'s Chief R&D Strategy Officer, transitioned to a part-time R&D Strategy Advisor due to health reasons. In his new role, Dr. Liu is no longer a Section 16 or executive officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
31.26 USD | +1.69% | +6.62% | +36.33% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.33% | 1.8B | |
+41.79% | 50.93B | |
-0.56% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+12.59% | 26.02B | |
-21.51% | 18.9B | |
+6.92% | 13.21B | |
+24.91% | 12.17B | |
+29.60% | 12.16B |
- Stock Market
- Equities
- PTGX Stock
- News Protagonist Therapeutics, Inc.
- Protagonist Therapeutics, Inc. Announces David Liu, Chief R&D Strategy Officer, Transitioned to Part-Time R&D Strategy Advisor